<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00849641</url>
  </required_header>
  <id_info>
    <org_study_id>UR-ST9201/09</org_study_id>
    <nct_id>NCT00849641</nct_id>
  </id_info>
  <brief_title>Muscle Tissue Oxygenation in Patients With Decompensated Liver Cirrhosis</brief_title>
  <official_title>Muscle Tissue Oxygenation in Patients With Decompensated Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Regensburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Regensburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with decompensated liver cirrhosis exhibit numerous hemodynamic and microvascular&#xD;
      changes, i.e., low systemic blood pressure and peripheral vasodilatation. In addition,&#xD;
      alterations of tissue oxygenation are described in these patients.&#xD;
&#xD;
      Near-infrared spectroscopy (NIRS) has been proposed as a tool to quantify microvascular&#xD;
      dysfunction, for example in patients with sepsis (1) or after trauma (2). NIRS is a&#xD;
      non-invasive technique that uses the differential absorption properties of oxygenated and&#xD;
      desoxygenated hemoglobin to evaluate skeletal muscle oxygenation (3).&#xD;
&#xD;
      Up to the investigators' knowledge no data exist on NIRS measurements in patients with&#xD;
      decompensated liver cirrhosis.&#xD;
&#xD;
      Aims of this study are to evaluate:&#xD;
&#xD;
        -  Are there any changes in NIRS parameters in patients with decompensated liver cirrhosis&#xD;
           in comparison to other critically ill patients (matched to SAPS II Score) or healthy&#xD;
           individuals?&#xD;
&#xD;
        -  Is there a correlation with common accepted prognostic scores (MELD Score or indocyanin&#xD;
           green clearance) in decompensated liver cirrhosis patients and initial NIRS parameters?&#xD;
&#xD;
        -  Does the NIRS trend within the first three days of ICU care in decompensated liver&#xD;
           cirrhosis patients receiving fluid replacement therapy correlate with the course of&#xD;
           disease?&#xD;
&#xD;
             1. De Backer D, Creteur J, Preiser JC, Dubois MJ, Vincent JL. Microvascular blood flow&#xD;
                is altered in patients with sepsis. Am J Respir Crit Care Med. 2002 Jul&#xD;
                1;166(1):98-104.&#xD;
&#xD;
             2. Creteur J. Muscle StO2 in critically ill patients. Curr Opin Crit Care. 2008&#xD;
                Jun;14(3):361-6.&#xD;
&#xD;
             3. Creteur J, Carollo T, Soldati G, Buchele G, De Backer D, Vincent JL. The prognostic&#xD;
                value of muscle StO2 in septic patients. Intensive Care Med. 2007&#xD;
                Sep;33(9):1549-56.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients fulfilling inclusion criteria and without exclusion criteria will be monitored by&#xD;
      NIRS using InSpectra™ technology (Hutchinson, USA) for the first three days of their ICU&#xD;
      hospitalization. Besides registration of the NIRS parameters (tissue hemoglobin saturation&#xD;
      (StO2), total tissue hemoglobin (THI), dynamic test values by using occlusion testing)&#xD;
      baseline characteristics (age, sex, SAPS II Score et.), disease relevant information&#xD;
      (etiology of liver cirrhosis, cause of ICU hospitalization) and ICU data (catecholamine&#xD;
      therapy, mechanical ventilation, hemodynamic monitoring, fluid therapy) will be recorded.&#xD;
      Within the observation time, an indocyanin green-clearance measurement and further laboratory&#xD;
      testing will be performed on a daily basis. Data will be pseudonymized and kept confidential&#xD;
      according to the guidelines of the local ethics committee.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">March 2011</completion_date>
  <primary_completion_date type="Anticipated">October 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>patients with decompensated liver cirrhosis admitted to the medical ICU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>critically ill patients without liver cirrhosis, matched to group 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>healthy control group</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients with decompensated liver cirrhosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with decompensated liver cirrhosis admitted to the medical ICU&#xD;
&#xD;
          -  written informed consent signed by the patients or his/her closest family member&#xD;
&#xD;
          -  age ≥ 18year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  no written informed consent signed by the patients or his/her closest family member&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvia Siebig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Regensburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sylvia Siebig, MD</last_name>
    <phone>+49 941 944</phone>
    <phone_ext>7010</phone_ext>
    <email>sylvia.siebig@klinik.uni-regensburg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93042</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Sylvia Siebig, MD</last_name>
      <phone>+49 941 944</phone>
      <phone_ext>7010</phone_ext>
      <email>sylvia.siebig@klinik.uni-regensburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Christian E Wrede, MD</last_name>
      <phone>+49 941 944</phone>
      <phone_ext>7010</phone_ext>
      <email>christian.wrede@klinik.uni-regensburg.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>February 20, 2009</study_first_submitted>
  <study_first_submitted_qc>February 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2009</study_first_posted>
  <last_update_submitted>February 20, 2009</last_update_submitted>
  <last_update_submitted_qc>February 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Sylvia Siebig, MD</name_title>
    <organization>University of Regensburg, Germany</organization>
  </responsible_party>
  <keyword>decompensation</keyword>
  <keyword>septic shock</keyword>
  <keyword>tissue oxygenation</keyword>
  <keyword>near infrared spectroscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

